HONG KONG, Jan. 18, 2011 (GLOBE NEWSWIRE) -- The Board of Directors of Sinobiomed Inc. (“Sinobiomed,” or the “Company”) (Pink Sheets:SOBM) is pleased to announce the sale of the Company’s wholly-owned BVI subsidiary, Wanxin Bio-Technology Limited (“Wanxin”) and its Chinese subsidiaries, Shanghai Wanxin Bio-Pharmaceutical Co Ltd. and Shanghai Bio-Science Cosmetic Co Ltd.
